Irinotecan
- Generic Name
- Irinotecan
- Brand Names
- Camptosar, Onivyde, Onivyde pegylated liposomal (previously known as Onivyde)
- Drug Type
- Small Molecule
- Chemical Formula
- C33H38N4O6
- CAS Number
- 97682-44-5
- Unique Ingredient Identifier
- 7673326042
- Background
Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothecin. Irinotecan was approved for the treatment of advanced pancreatic cancer in October, 2015 (irinotecan liposome injection, trade name Onivyde).
- Indication
For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluorouracil and leucovorin for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.
- Associated Conditions
- Esophageal Cancer, Ewing's Sarcoma, Gastric Cancer, High Grade Glioma: Glioblastoma (GBM), Metastatic Cervical Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Cancer, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Stage IV Colorectal Cancer, Recurrent, metastatic Colorectal carcinoma, Refractory, metastatic Pancreatic adenocarcinoma
- Associated Therapies
- -
Mesylate Apatinib Combined With Irinotecan in Treatment of Recurrent Small Cell Lung Cancer
- First Posted Date
- 2018-08-29
- Last Posted Date
- 2018-08-29
- Lead Sponsor
- Beijing Chest Hospital
- Target Recruit Count
- 90
- Registration Number
- NCT03651219
Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer
- Conditions
- Metastatic Gastroesophageal Junction AdenocarcinomaClinical Stage III Gastric Cancer AJCC v8Clinical Stage IV Gastric Cancer AJCC v8Unresectable Gastroesophageal Junction AdenocarcinomaClinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8Metastatic Gastric AdenocarcinomaUnresectable Gastric Adenocarcinoma
- Interventions
- First Posted Date
- 2018-08-22
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 14
- Registration Number
- NCT03641313
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Los Angeles General Medical Center, Los Angeles, California, United States
Irinotecan Plus Lobaplatin Versus Irinotecan in the Second-line Treatment of Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-08-03
- Last Posted Date
- 2020-02-05
- Lead Sponsor
- ShengFa Su
- Target Recruit Count
- 72
- Registration Number
- NCT03613753
- Locations
- 🇨🇳
The affiliated hospital of Guizhou medical university, Guiyang, Guizhou, China
Avelumab Combined With Cetuximab and Irinotecan for Treatment Refractory Metastatic Colorectal Microsatellite Stable Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-07-31
- Last Posted Date
- 2020-10-22
- Target Recruit Count
- 59
- Registration Number
- NCT03608046
- Locations
- 🇧🇪
Cliniques Universitaires Saint-Luc, Brussels, Belgium
🇧🇪Grand Hôpital de Charleroi, Charleroi, Belgium
A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies
- First Posted Date
- 2018-07-31
- Last Posted Date
- 2018-07-31
- Lead Sponsor
- Leaf Vertical Inc.
- Target Recruit Count
- 160
- Registration Number
- NCT03607643
- Locations
- 🇺🇸
Southwest Cancer Center, Orlando, Florida, United States
Evaluate the Efficacy of Irinotecan Versus Oxaliplatin in the First-line Treatment of Refractory Metastatic Colorectal Cancer
- First Posted Date
- 2018-06-26
- Last Posted Date
- 2018-06-26
- Lead Sponsor
- Peking University
- Target Recruit Count
- 130
- Registration Number
- NCT03567629
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
Irinotecan for Advanced and Metastatic Breast Cancer
- First Posted Date
- 2018-06-19
- Last Posted Date
- 2018-06-19
- Lead Sponsor
- Liaoning Tumor Hospital & Institute
- Target Recruit Count
- 124
- Registration Number
- NCT03562390
- Locations
- 🇨🇳
Cancer Hospital of China Medical University, Shenyang, Liaoning, China
SGT-53 in Children With Recurrent or Progressive CNS Malignancies
- Conditions
- Interventions
- First Posted Date
- 2018-06-13
- Last Posted Date
- 2022-02-08
- Lead Sponsor
- SynerGene Therapeutics, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT03554707
- Locations
- 🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States
A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-05-24
- Last Posted Date
- 2024-01-08
- Target Recruit Count
- 48
- Registration Number
- NCT03535727
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery
- Conditions
- Interventions
- First Posted Date
- 2018-05-23
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 537
- Registration Number
- NCT03533582
- Locations
- 🇺🇸
Henry Ford Health Saint John Hospital, Detroit, Michigan, United States
🇺🇸Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸Providence Alaska Medical Center, Anchorage, Alaska, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.